BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 34148870)

  • 21. Anti-TNF therapy is associated with decreased imaging and radiation exposure in patients with Crohn's disease.
    Patil SA; Rustgi A; Quezada SM; Flasar MH; Vandermeer F; Cross RK
    Inflamm Bowel Dis; 2013 Jan; 19(1):92-8. PubMed ID: 22508292
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Thiopurines are associated with a reduction in surgical re-resections in patients with Crohn's disease: a long-term follow-up study in a regional and academic cohort.
    van Loo ES; Vosseberg NW; van der Heide F; Pierie JP; van der Linde K; Ploeg RJ; Dijkstra G; Nieuwenhuijs VB
    Inflamm Bowel Dis; 2013 Dec; 19(13):2801-8. PubMed ID: 24189041
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of early anti-TNF use on clinical outcomes in Crohn's disease: a nationwide population-based study.
    Jung YS; Han M; Park S; Cheon JH
    Korean J Intern Med; 2020 Sep; 35(5):1104-1113. PubMed ID: 32306709
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increased Mortality Rates With Prolonged Corticosteroid Therapy When Compared With Antitumor Necrosis Factor-α-Directed Therapy for Inflammatory Bowel Disease.
    Lewis JD; Scott FI; Brensinger CM; Roy JA; Osterman MT; Mamtani R; Bewtra M; Chen L; Yun H; Xie F; Curtis JR
    Am J Gastroenterol; 2018 Mar; 113(3):405-417. PubMed ID: 29336432
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early Course of Inflammatory Bowel Disease in a Population-Based Inception Cohort Study From 8 Countries in Asia and Australia.
    Ng SC; Zeng Z; Niewiadomski O; Tang W; Bell S; Kamm MA; Hu P; de Silva HJ; Niriella MA; Udara WS; Ong D; Ling KL; Ooi CJ; Hilmi I; Lee Goh K; Ouyang Q; Wang YF; Wu K; Wang X; Pisespongsa P; Manatsathit S; Aniwan S; Limsrivilai J; Gunawan J; Simadibrata M; Abdullah M; Tsang SW; Lo FH; Hui AJ; Chow CM; Yu HH; Li MF; Ng KK; Ching JY; Chan V; Wu JC; Chan FK; Chen M; Sung JJ;
    Gastroenterology; 2016 Jan; 150(1):86-95.e3; quiz e13-4. PubMed ID: 26385074
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Indicators of suboptimal response to anti-tumor necrosis factor therapy in patients from China with inflammatory bowel disease: results from the EXPLORE study.
    Li J; Liu Z; Hu P; Wen Z; Cao Q; Zou X; Chen Y; Wang Y; Zhong J; Shen X; Demuth D; Fadeeva O; Xie L; Chen J; Qian J
    BMC Gastroenterol; 2022 Feb; 22(1):44. PubMed ID: 35120446
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A risk score system to timely manage treatment in Crohn's disease: a cohort study.
    Pallotta N; Vincoli G; Pezzotti P; Giovannone M; Gigliozzi A; Badiali D; Vernia P; Corazziari ES
    BMC Gastroenterol; 2018 Nov; 18(1):164. PubMed ID: 30400823
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Paternal use of medications for inflammatory bowel disease and the risk of hospital-diagnosed infections in the offspring: a nationwide cohort study.
    Friedman S; Garvik OS; Nielsen J; Nørgård BM
    Aliment Pharmacol Ther; 2022 Sep; 56(5):823-830. PubMed ID: 35770457
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term prognosis of the jejunal involvement of Crohn's disease.
    Park SK; Yang SK; Park SH; Park SH; Kim JW; Yang DH; Jung KW; Kim KJ; Ye BD; Byeon JS; Myung SJ; Yu CS; Kim JH
    J Clin Gastroenterol; 2013; 47(5):400-8. PubMed ID: 23269310
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phenotypic features of Crohn's disease associated with failure of medical treatment.
    Moran GW; Dubeau MF; Kaplan GG; Yang H; Seow CH; Fedorak RN; Dieleman LA; Barkema HW; Ghosh S; Panaccione R;
    Clin Gastroenterol Hepatol; 2014 Mar; 12(3):434-42.e1. PubMed ID: 23978351
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of Low Immunoglobulin G Levels on Disease Outcomes in Patients with Inflammatory Bowel Diseases.
    Horton N; Wu X; Philpott J; Garber A; Achkar JP; Brzezinski A; Lashner BA; Shen B
    Dig Dis Sci; 2016 Nov; 61(11):3270-3277. PubMed ID: 27619393
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Incidence of Bowel Surgery and Associated Risk Factors in Pediatric-Onset Crohn's Disease.
    Rinawi F; Assa A; Hartman C; Mozer Glassberg Y; Friedler VN; Rosenbach Y; Silbermintz A; Zevit N; Shamir R
    Inflamm Bowel Dis; 2016 Dec; 22(12):2917-2923. PubMed ID: 27755214
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: retrospective long-term follow-up of the LIR!C trial.
    Stevens TW; Haasnoot ML; D'Haens GR; Buskens CJ; de Groof EJ; Eshuis EJ; Gardenbroek TJ; Mol B; Stokkers PCF; Bemelman WA; Ponsioen CY;
    Lancet Gastroenterol Hepatol; 2020 Oct; 5(10):900-907. PubMed ID: 32619413
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Overall and Comparative Risk of Herpes Zoster With Pharmacotherapy for Inflammatory Bowel Diseases: A Nationwide Cohort Study.
    Khan N; Patel D; Trivedi C; Shah Y; Lichtenstein G; Lewis J; Yang YX
    Clin Gastroenterol Hepatol; 2018 Dec; 16(12):1919-1927.e3. PubMed ID: 29309905
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Stricturing and Fistulizing Crohn's Disease Is Associated with Anti-tumor Necrosis Factor-Induced Psoriasis in Patients with Inflammatory Bowel Disease.
    Weizman AV; Sharma R; Afzal NM; Xu W; Walsh S; Stempak JM; Nguyen GC; Croitoru K; Steinhart AH; Silverberg MS
    Dig Dis Sci; 2018 Sep; 63(9):2430-2438. PubMed ID: 29736839
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical features and predictors of clinical outcomes in Korean patients with Crohn's disease: a Korean association for the study of intestinal diseases multicenter study.
    Moon CM; Park DI; Kim ER; Kim YH; Lee CK; Lee SH; Kim JH; Huh KC; Jung SA; Yoon SM; Song HJ; Jang HJ; Kim YS; Lee KM; Shin JE
    J Gastroenterol Hepatol; 2014 Jan; 29(1):74-82. PubMed ID: 23981141
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Colonoscopy-guided therapy for the prevention of post-operative recurrence of Crohn's disease.
    Candia R; Bravo-Soto GA; Monrroy H; Hernandez C; Nguyen GC
    Cochrane Database Syst Rev; 2020 Aug; 8(8):CD012328. PubMed ID: 32746500
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Corticosteroid Sparing in Inflammatory Bowel Disease is More Often Achieved in the Immunomodulator and Biological Era-Results from the Dutch Population-Based IBDSL Cohort.
    Jeuring SFG; Biemans VBC; van den Heuvel TRA; Zeegers MP; Hameeteman WH; Romberg-Camps MJL; Oostenbrug LE; Masclee AAM; Jonkers DMAE; Pierik MJ
    Am J Gastroenterol; 2018 Mar; 113(3):384-395. PubMed ID: 29317770
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Stopping Mesalamine Therapy in Patients With Crohn's Disease Starting Biologic Therapy Does Not Increase Risk of Adverse Outcomes.
    Ungaro RC; Limketkai BN; Jensen CB; Yzet C; Allin KH; Agrawal M; Ullman T; Burisch J; Jess T; Colombel JF
    Clin Gastroenterol Hepatol; 2020 May; 18(5):1152-1160.e1. PubMed ID: 31419574
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inflammatory bowel disease and risk of small bowel cancer: a binational population-based cohort study from Denmark and Sweden.
    Axelrad JE; Olén O; Sachs MC; Erichsen R; Pedersen L; Halfvarson J; Askling J; Ekbom A; Sørensen HT; Ludvigsson JF
    Gut; 2021 Feb; 70(2):297-308. PubMed ID: 32474410
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.